田 洲 渠亚超 鲍旭丽 谢 云 郭 佳 闾 军.胸腺五肽显著增强干扰素在抗病毒治程中的特异性 CTL 效应[J].现代生物医学进展英文版,2015,15(7):1259-1262. |
胸腺五肽显著增强干扰素在抗病毒治程中的特异性 CTL 效应 |
Thymopentin 5 Significantly Enhanced the HBV-specific CTL Reactivity inInterferon Antiviral Therapy |
|
DOI: |
中文关键词: 慢性乙型肝炎 胸腺五肽 细胞毒性 T 淋巴细胞 |
英文关键词: Chronic Hepatitis B Thymopentin 5 Cytotoxic Lymphocyte |
基金项目:"215" 高层次卫生技术人才队伍建设工程培养计划学科带头人( 2011 -J.L.);首都医学发展科研基金( 2009-31 56) |
|
Hits: 975 |
Download times: 1317 |
中文摘要: |
目的: 探究在 e 抗原( HBeAg)阳性的慢性乙型肝炎患者采用 聚乙二醇干扰素 -2a (peg-2a)联合核苷类药物治疗 过程中, 加用
胸腺五肽对细胞免疫应答的影响。 方法: 选择采用 聚乙二醇干扰素alpha-2a 联合核苷类药物(拉米夫定 + 阿德福韦 酯)治疗 48 周 ,
HBeAg 仍为阳性,且 HLA-A2 阳性的慢性乙型肝炎患者 18 例, 分为两组。 一组原方案延长联合治疗作为 对照, 另 一组在原方案基
础上再加用 胸腺五肽治疗( 1 0 mg/ 次, 2 次 / 周, 共 24 周)治疗, 所有病人均治疗 至 96 周。 并做体外 HBV 特异性细胞毒 T 淋巴细
胞(HBV specific CTL)培养增殖, 通过 Elispot 技术分析其分泌细胞因 子( 肿瘤坏死因 子 -alpha, 干扰素 -r,白 介素 -10)的功能。 结果:
HBeAg 转阴 率, 治疗 96 周 时联合胸腺五肽组为 44.4 %( 4 /9), 原方案对照组为 22.2 %( 2 /9)。 HBsAg 滴度, 48 周 时, HBsAg 为
4571± 3772 IU/m:; 96 周时,联合胸腺五肽组为 1 962± 2869 IU/mL, 转阴 1 人,原方案对照组为 3490± 3124 IU/mL, P=0.093。 HBV
特异性 CTL 培养增殖, 96 周 时联合胸腺五肽组高于原方案对照组,且联合胸腺五肽组 TNF- 的分泌也高于原方案对照组, P<0.
05
。 结论: 胸腺五肽显著增强干扰素抗病毒治疗过程中的特异性 CTL 效应。 |
英文摘要: |
Objective:To investigate whether Thymopentin 5 (TP5) affects cellular immune during interferon antiviral therapy in
HBeAg-positive chronic hepatitis B patients.Methods:1 8 patients didn't achieve HBeAg seroconversion after peginterferon alpha-2a combined with lamivudine and adefovir dipivoxil for 48 weeks. They were randomly divided into two groups including continuing interferon
based combination therapy with (n=9) or without (n=9) TP5 (10 mg, twice a week for 24 weeks) till 96 weeks. We conduct in vitro HBV
specific CTL cultures and proliferation assays, HBcAg-induced cytokine secretion (INF-r, TNF-alpha, IL-1 0).Results:In TP5 administrated
group, the rate of HBeAg seroconversion was 44.4 %(4/9), mean HBsAg level was 1 962± 2869 IU/mL. In control group, the rate of
HBeAg seroconversion was 22.2 % (2 /9), mean HBsAg level was 3490± 3124 IU/mL. Proliferative response ofHBV specific CTL in TP5
administrated group was relatively strong at week 96. TNF-alpha production also increased at week 96 in TP5 administrated group, as compared to control group.Conclusion:Thymopentin 5 significantly enhanced the HBV-specific CTL reactivity in interferon antiviral therapy |
View Full Text
View/Add Comment Download reader |
Close |